Strategies to translate preclinical information to breast cancer patient benefit

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Despite the progress in understanding breast cancer biology, translation of basic findings into clinical applications still appears to be a complex process, and few molecular markers/signatures are in routine clinical use or currently challenged for their clinical utility. Disease complexity, certainly, represents an obstacle to successful translation, but methodological pitfalls in development and validation steps also contribute. Translational research should be planned as a round-trip from the bench to the bedside and back. The preoperative/neoadjuvant setting represents an ideal model because it allows identification and validation of treatment response predictors and of pharmacodynamic markers associated with clinical downstaging, investigations on in vivo action mechanism of drugs, and indirect validation of findings from preclinical models. Availability of well-annotated, high-quality biospecimens; standardized, reproducible, and robust assays to detect molecular markers/signatures even on few cells; prospective planning of study design; and regulatory issues adequately fitting preclinical and clinical needs represent fundamental assets for translational studies.

Original languageEnglish
Pages (from-to)55-59
Number of pages5
JournalJournal of the National Cancer Institute - Monographs
Issue number43
DOIs
Publication statusPublished - Oct 2011

Fingerprint

Translational Medical Research
Prospective Studies
Breast Neoplasms
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

@article{e29a4c003f4544fc89bfa0692de1df4b,
title = "Strategies to translate preclinical information to breast cancer patient benefit",
abstract = "Despite the progress in understanding breast cancer biology, translation of basic findings into clinical applications still appears to be a complex process, and few molecular markers/signatures are in routine clinical use or currently challenged for their clinical utility. Disease complexity, certainly, represents an obstacle to successful translation, but methodological pitfalls in development and validation steps also contribute. Translational research should be planned as a round-trip from the bench to the bedside and back. The preoperative/neoadjuvant setting represents an ideal model because it allows identification and validation of treatment response predictors and of pharmacodynamic markers associated with clinical downstaging, investigations on in vivo action mechanism of drugs, and indirect validation of findings from preclinical models. Availability of well-annotated, high-quality biospecimens; standardized, reproducible, and robust assays to detect molecular markers/signatures even on few cells; prospective planning of study design; and regulatory issues adequately fitting preclinical and clinical needs represent fundamental assets for translational studies.",
author = "Daidone, {Maria Grazia} and Nadia Zaffaroni and Vera Cappelletti",
year = "2011",
month = "10",
doi = "10.1093/jncimonographs/lgr033",
language = "English",
pages = "55--59",
journal = "Journal of the National Cancer Institute. Monographs",
issn = "1052-6773",
publisher = "Oxford University Press",
number = "43",

}

TY - JOUR

T1 - Strategies to translate preclinical information to breast cancer patient benefit

AU - Daidone, Maria Grazia

AU - Zaffaroni, Nadia

AU - Cappelletti, Vera

PY - 2011/10

Y1 - 2011/10

N2 - Despite the progress in understanding breast cancer biology, translation of basic findings into clinical applications still appears to be a complex process, and few molecular markers/signatures are in routine clinical use or currently challenged for their clinical utility. Disease complexity, certainly, represents an obstacle to successful translation, but methodological pitfalls in development and validation steps also contribute. Translational research should be planned as a round-trip from the bench to the bedside and back. The preoperative/neoadjuvant setting represents an ideal model because it allows identification and validation of treatment response predictors and of pharmacodynamic markers associated with clinical downstaging, investigations on in vivo action mechanism of drugs, and indirect validation of findings from preclinical models. Availability of well-annotated, high-quality biospecimens; standardized, reproducible, and robust assays to detect molecular markers/signatures even on few cells; prospective planning of study design; and regulatory issues adequately fitting preclinical and clinical needs represent fundamental assets for translational studies.

AB - Despite the progress in understanding breast cancer biology, translation of basic findings into clinical applications still appears to be a complex process, and few molecular markers/signatures are in routine clinical use or currently challenged for their clinical utility. Disease complexity, certainly, represents an obstacle to successful translation, but methodological pitfalls in development and validation steps also contribute. Translational research should be planned as a round-trip from the bench to the bedside and back. The preoperative/neoadjuvant setting represents an ideal model because it allows identification and validation of treatment response predictors and of pharmacodynamic markers associated with clinical downstaging, investigations on in vivo action mechanism of drugs, and indirect validation of findings from preclinical models. Availability of well-annotated, high-quality biospecimens; standardized, reproducible, and robust assays to detect molecular markers/signatures even on few cells; prospective planning of study design; and regulatory issues adequately fitting preclinical and clinical needs represent fundamental assets for translational studies.

UR - http://www.scopus.com/inward/record.url?scp=84855171233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855171233&partnerID=8YFLogxK

U2 - 10.1093/jncimonographs/lgr033

DO - 10.1093/jncimonographs/lgr033

M3 - Article

SP - 55

EP - 59

JO - Journal of the National Cancer Institute. Monographs

JF - Journal of the National Cancer Institute. Monographs

SN - 1052-6773

IS - 43

ER -